<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994006</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-7339-09-SMC</org_study_id>
    <nct_id>NCT00994006</nct_id>
  </id_info>
  <brief_title>The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects</brief_title>
  <official_title>The Absorption of Supplemental Magnesium Oxide Compared to Magnesium Citrate in Healthy Subjects With no Apparent Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The magnesium food content in the Western world is consistently reducing. Hypomagnesemia is
      common in hospitalized patients, especially in the elderly with coronary artery disease (CAD)
      and/or those with chronic heart failure. Hypomagnesemia is associated with increased
      incidence of diabetes mellitus, metabolic syndrome, mortality rate from coronary artery
      disease (CAD) and all cause. Magnesium supplementation improves myocardial metabolism,
      inhibits calcium accumulation and myocardial cell death; it improves vascular tone,
      peripheral vascular resistance, afterload and cardiac output, reduces cardiac arrhythmias and
      improves lipid metabolism. Magnesium also reduces vulnerability to oxygen-derived free
      radicals, improves human endothelial function and inhibits platelet function, including
      platelet aggregation and adhesion. The data regarding the absorption difference between
      supplemental magnesium oxide and magnesium citrate in humans is spare.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two oral preparations of magnesium are available in Israel:

        1. Magnesium Diasporal (magnesium citrate, elemental magnesium 98.6 mg), PROTINA GMBH,
           ISMANING, Germany

        2. Magnox 520 TM (magnesium oxide, 520 mg elemental magnesium), Naveh Pharma Ltd., Israel.

      The data regarding the absorption difference between the two supplemental magnesium
      preparations (magnesium oxide and magnesium citrate) in humans is spare.

      Primary objective: To find out the absorption of magnesium citrate compared to magnesium
      oxide in healthy subjects with no apparent heart disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intracellular magnesium levels will be assessed</measure>
    <time_frame>30-day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet function tests</measure>
    <time_frame>30-day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Hypomagnesemia</condition>
  <arm_group>
    <arm_group_label>Magnesium oxide tables</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be instructed to take Magnox 520 qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium citrate tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be instructed to take magnesium diasporal tablets t.i.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium oxide</intervention_name>
    <description>520 mg of elemental magnesium q.d.</description>
    <arm_group_label>Magnesium oxide tables</arm_group_label>
    <other_name>Magnox 520 TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Magnesium citrate</intervention_name>
    <description>Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.</description>
    <arm_group_label>Magnesium citrate tablets</arm_group_label>
    <other_name>Magnesium Diasporal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 20-70 years

          2. Healthy subjects

        Exclusion Criteria:

          1. Chest pain

          2. Diabetes mellitus

          3. Documented coronary artery disease

          4. Asthma or any lung disease

          5. Chronic diarrhea

          6. Chronic renal failure (serum creatinine&gt; 3 mg/dL)

          7. Hypo or hyperthyroidism

          8. Heart failure

          9. On any chronic therapy/medications

         10. Malabsorption

         11. AV block

         12. Pacemaker

         13. Any malignancy

         14. Obesity &gt; 30 kg/m2 body mass index

         15. Smokers

         16. Pregnancy

         17. Alcohol or drug abuse

         18. Any chronic inflammation

         19. Refuse to sign inform consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Shechter, MD, MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Leviev Heart Center, Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Leviev Heart Center, Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer, Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.heart.sheba.co.il</url>
    <description>The Leviev Heart Center</description>
  </link>
  <reference>
    <citation>Shechter M. Magnesium and cardiovascular system. Magnes Res. 2010 Jun;23(2):60-72. doi: 10.1684/mrh.2010.0202. Epub 2010 Mar 31. Review.</citation>
    <PMID>20353903</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Shechter, MD, MA, PI</name_title>
    <organization>Leviev Heart Center, Sheba Medical Center</organization>
  </responsible_party>
  <keyword>Magnesium</keyword>
  <keyword>nutrition</keyword>
  <keyword>platelets</keyword>
  <keyword>aggregation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
    <mesh_term>Magnesium Oxide</mesh_term>
    <mesh_term>Levulinic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

